Abstract: Mindray is seeking to raise at least USD500m via a Hong Kong listing. Huatai and JPM are the deal sponsors. This note covers Mindray's in vitro diagnostics, patient monitoring and life support, medical imaging, and peer valuation. We also discuss our preliminary thoughts on valuation.
COFOE MEDICAL, HENGRUI PHARMA, CHUNLI MEDICAL, FOSUN PHARMA, WUXI APPTEC, SH PHARMA, Mindray, SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING, JIANGSU HENGRUI MEDICINE, SHANGHAI PHARMACEUTICALS, AUTOBIO DIAGNOSTICS, HAOHAI BIOTEC, Nihon Kohden, Sysmex, BEIJING CHUNLIZHENGDA MEDICAL INSTRUMENTS, SHANGHAI UNITED IMAGING HEALTHCARE, SH Haohai Biological, GE HealthCare Technologies Inc. Common Stock
Research on Hong Kong and A+H equity offerings, from the first filing to the aftermarket. Coverage includes pre-IPO early thoughts on the business and valuation, analysis of the final deal terms and cornerstone investors, and updates as new prospectus versions are filed.
Interested in the full report? Get in touch with our team.